<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924974</url>
  </required_header>
  <id_info>
    <org_study_id>L2015108</org_study_id>
    <nct_id>NCT02924974</nct_id>
  </id_info>
  <brief_title>Spinal Morphine in Robotic Assisted Radical Prostatectomy</brief_title>
  <acronym>SALMON-RARP</acronym>
  <official_title>Spinal Morphine in Robotic Assisted Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maasstad Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maasstad Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate if a single shot of spinal morphine will increase patient
      satisfaction when compared to intravenous morphine in Robot-Assisted Radical Prostatectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized controlled trial. It will randomize 160 patients who are scheduled
      for Robot-Assisted Radical Prostatectomy. The intervention group will receive a single spinal
      injection of a bupivacaine (12,5 mg)/morphine(300 mcg) mixture. Controlgroup will receive a
      subcutaneous injection of lidocaïne for placebo purposes and an intravenous loading dose of
      morphine at the end of surgery.

      Both groups will receive general anesthesia during surgery in a standardized fashion.

      After the surgery, both groups will receive a Patient-Controlled Analgesia pump for
      post-operative pain control.

      Primary outcome is patient satisfaction as measured by the Quality-of-Recovery-15
      questionnaire. This questionnaire will be taken at baseline, day 2 and 1 week after surgery.

      Secundary outcomes are morphine use per PCA, duration of hospital stay, side-effects and ease
      of surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>day 1</time_frame>
    <description>Quality of Recovery-15 questionnaire</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Morphine</condition>
  <condition>Injections, Spinal</condition>
  <condition>Prostatectomy</condition>
  <condition>Patient Satisfaction</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>subcutaneous lidocaïne and intravenous loading dose of morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spinal injection of 4 or 5 ml of bupivacaine/morphine 2,5 mg/ml/60mcg/ml. The reduction to 4 ml is for patients over 75 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>mixed with bupivacaine</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>sham procedure (s.c. lidocaïne)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for Robot-Assisted Radical Prostatectomy

        Exclusion Criteria:

          -  Contra-indications to spinal anesthesia (severe aortic stenosis, coagulation
             disorders)

          -  Contra-indications to study medication (local anesthetics, morphine, paracetamol,
             metamizol)

          -  Conversion to an open procedure

          -  Post-operative ICU-admission
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seppe Koopman, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Maasstad Ziekenhuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aart Jan W Teunissen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maasstad Ziekenhuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark V Koning, MD, DESA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maasstad Ziekenhuis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark V Koning, MD, DESA</last_name>
    <email>KoningM2@maasstadziekenhuis.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aart Jan W Teunissen, MD</last_name>
    <email>TeunissenA@maasstadziekenhuis.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark V Koning, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

